drugset / Trial / NCT06783816
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
NaSequentialOpen-labelTreatment
Summary
The is a multicenter, single arm, open label clinical study on the novel CAR-T combined expression of IL-15 in the treatment of malignant hematological tumors.Plan to recruit 45 subjects with malignant hematological tumors.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | chimeric antigen receptor gene modified T cells | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | chimeric antigen receptor gene modified T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | chimeric antigen receptor gene modified T cells | Cell therapy | 1.5e+06 cells/kg | Intravenous |
| Subject | chimeric antigen receptor gene modified T cells | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | chimeric antigen receptor gene modified T cells | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | chimeric antigen receptor gene modified T cells | Cell therapy | 5e+06 cells/kg | Intravenous |